Physician profile
Bhanu Singh
NPI 1457714636
$1,679.16
in general payments reported to CMS, 2019-2025
14 companies · $648 in 2025
The $648 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $130 · 2023: $284 · 2024: $617 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $293.35 | 2022-2025 | Axios, Spyglass, Agile Esophageal |
| Olympus America INC. | $215.18 | 2024-2025 | Endoclot Sis, Hanarostent Esophagus Tts(Ccc), Endoclot Phs |
| Cook Medical LLC | $206.54 | 2025 | Fusion, Hemospray, Fusion Quattro |
| Steris Corporation | $163.77 | 2024-2025 | |
| Abbvie INC. | $159.12 | 2025 | |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2023 | Imfinzi |
| 3-D Matrix, INC. | $131.14 | 2024 | |
| Phathom Pharmaceuticals, INC. | $73.50 | 2024-2025 | Voquezna |
| Conmed Corporation | $50.89 | 2023-2024 | Conmed Biliary |
| Erbe USA INC | $30.00 | 2024 | Vio300d |
| W. L. Gore & Associates, INC. | $29.72 | 2022 | |
| Inspire Medical Systems, INC. | $23.84 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $17.11 | 2024 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhanu Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.